Prognosis
CoronaVac’s Overall Efficacy in Brazil Measured at 50.4%
- New numbers add to confusion over Chinese-developed vaccine
- 78% rate presented last week had excluded very mild cases
Photographer: Jonne Roriz/Bloomberg
This article is for subscribers only.
Brazil officials said the CoronaVac vaccine developed in partnership with Sinovac Biotech Ltd was 50.38% effective in preventing coronavirus cases, a number that meets the threshold required by global regulators for approval but that’s well below the 78% figure announced last week.
At a press conference Tuesday, Sao Paulo state officials and researchers from Butantan Institute explained that they split the cases in six categories: asymptomatic, very mild, mild, two levels of moderate, and severe -- the first two not requiring medical assistance.